NCT03134547

Brief Summary

This study was performed to compare the incidence of EA between two dose of sevoflurane for sedation with caudal block in children, and intended to find the optimal dose for prevention of sevoflurane induced emergence agitation

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2016

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 1, 2017

Completed
Last Updated

May 1, 2017

Status Verified

April 1, 2017

Enrollment Period

7 months

First QC Date

April 21, 2017

Last Update Submit

April 28, 2017

Conditions

Keywords

emergence agitationsevofluranechildren

Outcome Measures

Primary Outcomes (4)

  • postoperative agitation score

    Four-point agitation scale

    5 minutes in the recovery room

  • postoperative agitation score

    Four-point agitation scale

    30 minutes in the recovery room

  • postoperative agitation score

    Pediatric Anesthesia Emergence Delirium (PAED) scale

    5 minutes in the recovery room

  • postoperative agitation score

    Pediatric Anesthesia Emergence Delirium (PAED) scale

    30 minutes in the recovery room

Study Arms (2)

low volume volatile anesthetics

ACTIVE COMPARATOR

1.0 % sevoflurane sedation via face mask , low dose sevoflurane group

Drug: low dose sevoflurane group

high volume volatile anesthetics

ACTIVE COMPARATOR

2.5 % sevoflurane sedation via face mask, high dose sevoflurane group

Drug: high dose sevoflurane group

Interventions

low volume volatile anesthetics (1.0%)

Also known as: 1.0 %sevoflurane
low volume volatile anesthetics

high volume volatile anesthetics (2.5%)

Also known as: 2.5% sevoflurane
high volume volatile anesthetics

Eligibility Criteria

Age1 Year - 5 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • patients undergoing elective subumbilical surgery, American society of anesthesiologist physical status classification 1

You may not qualify if:

  • Children with development delay, anxiety disorder, or a history of allergy to any study drugs, or severe systemic disease were excluded from this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. Anesthesiology. 2004 May;100(5):1138-45. doi: 10.1097/00000542-200405000-00015.

  • Aono J, Ueda W, Mamiya K, Takimoto E, Manabe M. Greater incidence of delirium during recovery from sevoflurane anesthesia in preschool boys. Anesthesiology. 1997 Dec;87(6):1298-300. doi: 10.1097/00000542-199712000-00006.

MeSH Terms

Conditions

Emergence Delirium

Interventions

Sevoflurane

Condition Hierarchy (Ancestors)

DeliriumConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Methyl EthersEthersOrganic ChemicalsHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbons

Study Officials

  • Eun kyung Choi, MD,PhD

    Yeungnam University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 21, 2017

First Posted

May 1, 2017

Study Start

June 1, 2016

Primary Completion

December 31, 2016

Study Completion

February 28, 2017

Last Updated

May 1, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will share